Efficacy and side effects of monotherapy risperidone, olanzapine and quetiapine in previously untreated patients with schizophrenia: a one-year prospective cohort study

Shanghai Archives of Psychiatry

Volumn 23, Issue 3, 2011, Pages 137-147

  Yang, Xiao Min ^a   Zhang, Hong Xia ^b   Wang, Hui Fang ^a   Zhou, Hui ^a   Jiang, Kai Da ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Olanzapine; Quetiapine; Risperidone; Schizophrenia; Therapeutic efficacy

Indexed keywords

EID: 84876341669     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1002-0829.2011.03.002     Document Type: Article

References (20)

1. Davis J M, Chen N, Click I D. A Meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 2003, 60(6): 553-564.
2. Leucht S, Komossa k, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotic in the treatment of schizophrenia. Am J Psychiatry, 2009, 166(2): 152-163.
3. Johnsen E, Kroken R A, Wentzel-Larsen T, Jorgensen H A. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry, 2010, 10: 26.
4. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 2005, 353(12): 1209-1223.
5. McEvoy J P, Lieberman J A, Perkins D O, Hamer R M, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-Week comparison. Am J Psychiatry, 2007, 164(7): 1050-1060.
6. Mi G I, Tang M Q, Wang Y Y, Huang J S, Gao X M, Zhai J. Effect of quetiapine and sulpiride on quality of life in the treatment of first-episode schizophrenia. Chinese Journal of Nervous and Mental Diseases, 2009, 35(9): 535-538. (in Chinese)
7. Yang F D, Chen S, Wang X Q, Zhang X B, Li M, Zhou J C, et al. Efficacy and safety of the domestic risperidone in patients with schizophrenia: a random, double-blind, controlled trial. Chinese Mental Health Journal, 2009, 23(7): 498-503. (in Chinese)
8. Zhang B, Wang X, Cao Y, Xu X F, Meng H Q, Zhao J P, et al. Comparison in the therapeutic efficacy of perospirone and risperidone in the treatment of 232 patients with schizophrenia. West China Journal of Pharmaceutical Science, 2007, 22(6): 707-708. (in Chinese)
9. Rong D S, Wei Z G, Bao G. Comparison of early treatment response comparisons among olanzapine, risperidone, quetiapine, chlorpromazine for schizophrenia. China Modern Doctor, 2010, 48(11): 19-20. (in Chinese)
10. He Y I, Zhang M Y. Positive and negative syndrome scale and its implication. Journal of Clinical Psychiatry, 1997, 7(6): 353-355. (in Chinese)
11. Si T M, Yang J Z, Shu L, Wang X L, Kong Q M, Zhou M, et al. The reliability, validity of PANSS and its implication. Chinese Mental Health Journal, 2004, 18(1): 45-47. (in Chinese)
12. Zhang M Y. Side effect rating scale. Shanghai Arch Psychiatry, 1984, (2): 77-80. (in Chinese)
13. Sun Z Q, Xu Y Y. Medical statistics. Beijing: People's Medical Publishing House, 2010: 121-122; 139-142. (in Chinese)
14. Kinon B J, Stauffer V L, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely III patients with schizophrenia. J Clin Psychopharmacol, 2008, 28(6): 601-607.
15. Maloney A E, Sikich L. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr Dis Treat, 2010, 6: 749-766.
16. Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aquilar J, Caro O, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry, 2005, 66(8): 1021-1030.
17. Novick D, Haro J M, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res, 2009, 108(1-3): 223-230.
18. Novick D, Haro J M, Bertsch J, Haddad P M. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-mouth results from the European schizophrenia outpatients health outcomes study. J Clin Psychopharmacol, 2010, 30(5): 531-540.
19. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull, 2010 May 31. [Epub ahead of print] http://schizophreniabulletin.oxfordjournals. org/content/early/2010/05/30/schbul.sbq042.long
20. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rew, 2010, (3): CD006654.